ArticleAmerican journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons2026
Evaluation of kidney procurement biopsy and machine perfusion on allograft outcomes: A retrospective cohort study of the Organ Procurement and Transplantation Network database.
Article in American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Time-Zero Kidney Biopsy and Deceased-Donor Transplant Outcomes: A Systematic Review and Meta-Analysis of Prognostic Value, Prediction, and Clinical Utility.Medical sciences (Basel, Switzerland) · 2026Pooled it
- The pre-implantation biopsy story is not over yet.The Lancet regional health. Europe · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Procurement biopsy and machine perfusion parameters can be utilized to assess donor kidney quality, but information may be incongruent. Using the Organ Procurement and Transplantation Network database from 2014 to 2022, we performed a retrospective cohort study of all adult recipients of solitary kidneys with a Kidney Donor Profile Index of 35% to 85%, which were biopsied and machine-perfused (N = 13 962). The biopsies were separated into "low" (≤10%), "intermediate" (11%-20%), and "high" (>20%) glomerulosclerosis (GS). The perfusion parameters were separated into "good" and "poor" based on a final resistance of 0.4 and a final flow rate of 100 mL/min. As GS and perfusion worsened, there were worsening trends for primary nonfunction, stage 4 chronic kidney disease at 1 year, and death-censored graft survival. In multivariable analyses, compared with their reference groups, high GS had a greater effect than poor perfusion on graft survival. Machine perfusion parameter thresholds appeared to delineate better-quality organs for kidneys with low and intermediate GS results. However, good perfusion may not distinguish outcomes in those with high GS. Despite this, allografts with high GS and poor perfusion still had a mean death-censored graft survival of 5.9 years. This information, together with careful donor-recipient matching, may assist in kidney utilization for the appropriate recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.